Royal College of Pathologists
Luiza Moore MD PhD is a distinguished pathologist and researcher with extensive experience in clinical diagnostics and pathology. Currently serving as a member of the Board of Directors for the Digital Pathology Association and as Senior Director of Clinical Diagnostics for Global Oncology at AstraZeneca, Luiza has held various leadership roles, including Director of Translational Pathology. At Cambridge University Hospitals NHS Foundation Trust, Luiza specializes in gynaecological pathology, particularly endometrial and ovarian cancers. A Fellow of the Royal College of Pathologists, Luiza also has contributed to research as a Career Development Fellow at the Wellcome Sanger Institute, focusing on genomics and computational pathology. Additional roles have included advisory positions at Microsoft and directorships in clinical development at Cyted, complemented by a strong educational background from the University of Cambridge and other prestigious institutions.
This person is not in any offices
Royal College of Pathologists
1 followers
Pathology is the science at the heart of modern medicine, vital for the diagnosis and clinical management of disease. It is the science behind the cure, or the hidden science that saves lives. Although some pathologists work in laboratories, many work directly with patients in hospitals and the community. Together they are involved in over 70% of all diagnoses, as well as playing an important role in disease prevention, treatment and monitoring. The College is a professional membership organisation committed to setting and maintaining professional standards and to promoting excellence in the practice of pathology. The College aims to advance the science and practice of pathology, to provide public education, to promote research in pathology and to disseminate the results. It is a registered charity. The College was founded in 1962 and received its Royal Charter in 1970. There are 11,000 members worldwide practicing in the 19 pathology specialties. Approximately 78% of the membership are medically qualified, with the remaining 22% being senior clinical scientists.